PDCD1 and hepatocellular carcinoma: Detailed phenotypic flow cytometry investigations of fresh biopsies acquired from progressed HCC patients before anti-PD-1/PD-L1 therapy revealed that responders to anti-PD-1/PD-L1 treatment had a high baseline incidence of PD-1 high CD8+ T cells in malignant cells [32].